Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Eugene M. Sorkin"'
Autor:
Eugene M. Sorkin
Publikováno v:
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 30(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02434cd75a4e4e162b6f9cac3d3c5e48
https://pubmed.ncbi.nlm.nih.gov/34860902
https://pubmed.ncbi.nlm.nih.gov/34860902
Autor:
Milap C. Nahata, Eugene M. Sorkin
Publikováno v:
Annals of Pharmacotherapy. 53:959-961
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e9d07cdb39d6652c6db0de52d6f258
https://doi.org/10.1177/1060028019849941
https://doi.org/10.1177/1060028019849941
Autor:
Eugene M. Sorkin, Anthony Markham
Publikováno v:
Drugs & Aging. 14:63-71
▲ Cilostazol is an antiplatelet agent with vasodilating properties that has been used in the treatment of patients with peripheral ischaemia such as intermittent claudication. ▲ The drug inhibits platelet aggregation induced by ADP, collagen and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edbc34d3d58dd7f07051242b7256bc34
https://doi.org/10.2165/00002512-199914010-00005
https://doi.org/10.2165/00002512-199914010-00005
Autor:
Eugene M. Sorkin, Rex N. Brogden
Publikováno v:
Drugs. 49:618-649
Since the earlier review in Drugs substantial additional data have accumulated regarding the antihypertensive efficacy of isradipine in various clinical situations, as well as data on its clinical effects in atherosclerosis. Recent therapeutic trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e697ca2b14ae23245c30794a276c42f
https://doi.org/10.2165/00003495-199549040-00009
https://doi.org/10.2165/00003495-199549040-00009
Publikováno v:
Drugs & Aging. 5:446-474
Etidronic acid is an orally and intravenously active bisphosphonate, which is believed to inhibit resorption of bone via a number of cellular mechanisms, including alteration of osteoclastic activity. In studies of patients with symptomatic Paget's d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41dc6f2ed9955c8e4625214fc7eb400e
https://doi.org/10.2165/00002512-199405060-00006
https://doi.org/10.2165/00002512-199405060-00006
Autor:
Harriet M. Bryson, Eugene M. Sorkin
Publikováno v:
Drugs. 48:894-906
By cleaving neutrophil-derived DNA present in the infected lungs of patients with cystic fibrosis (CF), dornase alfa (recombinant human deoxyribonuclease I) reduces the adhesiveness and viscoelasticity of CF sputum. Well designed clinical studies per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ef54d8434f2c63e5121a802e4712c2a
https://doi.org/10.2165/00003495-199448060-00006
https://doi.org/10.2165/00003495-199448060-00006
Autor:
Eugene M. Sorkin, David H. Peters
Publikováno v:
Drugs. 46:177-208
Finasteride is a novel therapeutic agent that selectively inhibits the enzyme 5 alpha-reductase, thereby reducing prostatic dihydrotestosterone (DHT) levels and prostate size. In men with symptomatic benign prostatic hyperplasia (BPH), these effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cacbf22d1f3ac6cd264662f4917ec366
https://doi.org/10.2165/00003495-199346010-00010
https://doi.org/10.2165/00003495-199346010-00010
Autor:
Eugene M. Sorkin, Anthony Markham
Publikováno v:
Drugs. 45:931-952
Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy. Since the publication of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010d572fd559eeb3eb379018fc9c3cee
https://doi.org/10.2165/00003495-199345060-00006
https://doi.org/10.2165/00003495-199345060-00006
Autor:
Eugene M. Sorkin, Donna McTavish
Publikováno v:
Drugs. 42:65-89
Pravastatin is an HMG-CoA reductase inhibitor which reduces plasma cholesterol levels by inhibiting de novo cholesterol synthesis and increasing the receptor-mediated catabolism of low density lipoprotein (LDL). Several large multicentre placebo-cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e15f464fc4a0b11b630c220122f5a55
https://doi.org/10.2165/00003495-199142010-00005
https://doi.org/10.2165/00003495-199142010-00005
Publikováno v:
Drugs & Aging. 1:228-248
Selegiline (deprenyl) is a selective inhibitor of cerebral monoamine oxidase type B at the dosage (10 mg/day) used in patients with Parkinson's disease. Through this activity, the drug increases nigrostriatal dopamine levels, and may protect neurons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ab952624ccc34be7b67599dbcc30fff
https://doi.org/10.2165/00002512-199101030-00006
https://doi.org/10.2165/00002512-199101030-00006